Tuesday, June 03, 2025

FRACKING

Major demo keeps quaise energy on track to power the world with clean, renewable geothermal energy



CEO cites three-tier approach to developing resource




Science Communications

Quaise-Nabors (2).JPG 

image: 

Drone image of the setup for the first demonstration of Quaise Energy’s novel drilling technique on a full-scale oil rig.

view more 

Credit: Quaise Energy





HOUSTON, Texas--Quaise Energy has moved out of the lab and into the field with the first demonstration of its novel drilling technique on a full-scale oil rig just outside of Houston. The company, formed only seven years ago, is on track to prove that clean, renewable geothermal energy could power the world, according to Carlos Araque, CEO of Quaise and a co-founder.

“Geothermal energy is available everywhere on massive scales,” said Araque. “If you take all fossil, all nuclear, and all other forms of renewable energy combined, they’re not even a millionth of a millionth of the thermal stores of energy” below the Earth’s surface. “It’s mind-boggling, and to get it, we only have to go down two to twelve miles. That’s how close we are to infinite clean energy no matter where you are in the world.”

Araque was speaking on May 21 at the first demonstration of the company’s drilling technology at a full-scale oil rig owned by Nabors, one of the world’s largest oil-and-gas drilling companies. Among the approximately 50 attendees, who included reporters, potential investors, and even potential Quaise customers, was William Restrepo, CFO of Nabors and a Quaise board member. Also on hand was Lauren Boyd, director of the Geothermal Technologies Office at the U.S. Department of Energy.

Superhot, Superdeep

Geothermal energy--the heat beneath our feet--has been around for a long time, but it barely contributes to today’s energy mix. “That’s because the true geothermal resource, the one that matters, is not very accessible. Getting to it is beyond the economic reach of the conventional tool set of oil and gas,” said Araque.

The mother lode of geothermal energy is some two to 12 miles beneath the Earth’s surface where the rock is so hot that if water could be pumped to the area it would become supercritical, a steam-like phase that most people aren’t familiar with. (Familiar phases are liquid water, ice, and the vapor that makes clouds.) Supercritical water, in turn, can carry some 5-10 times more energy than regular hot water, making it an extremely efficient energy source if it could be pumped above ground to turbines that could convert it into electricity.

Today we can’t access those resources, except in places like Iceland where they are relatively close to the surface. The number one problem: we can’t drill down far enough. The drills used by the oil and gas industries can’t withstand the formidable temperatures and pressures that are found miles down without becoming exponentially more expensive with depth.

Quaise is working to replace the conventional drill bits that mechanically break up the rock with millimeter-wave energy (cousins to the microwaves many of us cook with). Those millimeter waves literally melt then vaporize the rock to create ever-deeper holes.

Steady Progress

The May demo at the Nabors facility is only the latest of many in what Araque calls an aggressive timeline to prove the technology. The ultimate goal, he said, is to provide a renewable source of energy on parity with oil and gas. “This is not a company built to develop a cool drilling gadget. We aim to become a geothermal developer. Our product is not a drill bit. Our product is clean heat and energy that is abundant, reliable and affordable on a global scale,” said Araque.

The general technique behind the Quaise drilling approach was developed at MIT over some 15 years. Scientists there showed that millimeter waves could indeed drill a hole in basalt (basalt and granite make up the majority of rock at great depth). This was promising in part because the gyrotron machine that produces the millimeter-wave energy is not new. It’s been used for some 70 years in research toward nuclear fusion as an energy source.

Quaise has been developing the technique to drill deeper and deeper holes. The holes drilled at MIT were two inches in diameter by two inches deep. Outside the Quaise lab in Houston earlier this year, engineers succeeded in drilling a hole four inches in diameter and 10 feet deep (see video).

Andres Calabressi, Head of Manufacturing at Quaise, emceed the Quaise demonstration with a microphone to communicate over the steady rumble of powerful equipment. He explained that beginning in March, the company lowered columns of granite about nine inches in diameter into a conventionally drilled hole under the rig. Together those columns made a core some 80 feet long that sits inside a metal casing. The latter is outfitted with ports to monitor parameters like heat and pressure, data that allow the team to test recipes for optimal drilling.

The Quaise engineers then integrated the millimeter-wave technology with the rig. In the May 21 demo, they shot millimeter waves into the granite column, deepening a hole four inches in diameter that they’d already drilled to ten feet. (The next week, the team successfully drilled to 30 feet for the first time; the next goal on this phase of the work is 40 feet.)

During the demonstration, Calabressi was flanked by three large flat screens showing different dimensions of the work. One tracked key parameters like rock temperature, while another showed a video close-up of the millimeter waves melting rock. (The latter was taken previously in the Quaise lab since those interactions were not visible at the Nabors rig.)

Araque noted that the demo was “full scale in size, but not in power.” The gyrotron involved produced 100 kilowatts of power. “That’s a tenth of the power that will be commercially relevant, and is roughly equivalent to the power of the car you drove to this demonstration.”

Next month, Quaise expects the delivery of a much larger gyrotron capable of producing one megawatt of power. “That is commercially relevant. We aim to get it to the field over the next two years,” Araque said.

In the meantime, the company is preparing for another demonstration planned for July in Marble Falls, Texas. There, the team aims to drill multiple holes 130 meters (about 425 feet) deep into an actual granite outcrop for the first time. Henry Phan is Vice President of Engineering at Quaise. He explained that the Marble Falls rig will be smaller, “allowing us to be more nimble in terms of moving from one hole to another.”

Additional Advances

Quaise has also been tackling other scientific and engineering challenges associated with harvesting the energy from superhot, superdeep rock. Trenton Cladouhos, vice president of geothermal resource development at Quaise, described several of those challenges and advances toward solving them in a talk the day before the Quaise demo at the Geothermal Transition Summit North America in Houston.

Cladouhos said that Quaise is working with vendors and universities “to push them to consider higher and higher temperatures.” For example, last year a team at the Ecole Polytechnique Fédéral de Lausanne reported new insights into what happens when superhot, superdeep rock is exposed to water that can eventually transfer the rocks’ heat to the surface. The work, supported in part by Quaise, was published in the journal Nature Communications. It confirmed earlier modeling work also supported by Quaise.

In addition, Cladouhos noted that Quaise has an in-house engineer who has been working on the design of superhot geothermal power plants. Earlier this year Senior Mechanical Engineer Daniel Dichter reported insights to that end in two papers.

Toward the Future

Araque concluded his presentation at the demo by describing the company’s blueprint for developing a superhot, superdeep geothermal resource available around the globe. It involves dividing the world into three tiers based on geothermal gradient, or how close the resource is to the surface. Tier 1, for example, will focus on relatively accessible superhot rock. This means that the first Quaise power plant will probably be located in the American West, perhaps near the Newberry Volcano site in Oregon. Newberry has a long history of geothermal exploration.

Although still a ways off, Tier III sites, which will involve drilling as much as 12 miles down, “hold the key to making superhot geothermal a truly global energy source,” according to this Quaise video. “Tier III sites could provide power to more than 90% of humanity.”

Superhot Team

Araque described Quaise’s goal of unlocking superhot, superdeep energy for the world as “a moonshot. But it is not a moonshot.” The people working to “pioneer this transformative approach to clean energy have transitioned from careers in oil, gas, nuclear fission, and nuclear fusion,” and all have histories of achievement.

For example, several were involved in the invention and development of Manara, a production and reservoir management solution developed at Schlumberger to substantially increase the recovery of oil from complex production systems. And among them, Quaise team members hold several patents.

“So I’m confident that together we can make this work,” Araque concludes.

--END—

By Elizabeth A. Thomson, Correspondent for Quaise Energy

Andres Calabressi, Head of Manufacturing at Quaise Energy, emcees the first demonstration of the company’s novel drilling technique on a full-scale oil rig.

World's irst MMW Hybrid Drilling Rig [VIDEO] | 

In this video, Andres Calabressi, Head of Manufacturing at Quaise Energy, describes the first demonstration of the company’s novel drilling technique on a full-scale oil rig.

Credit

Quaise Energy


 

Clinical research on psychedelics gets a boost from new study



Consensus on how mindset and surroundings shape therapy outcomes is an important step toward regulatory approval for use of drugs like MDMA and psilocybin in treatment of debilitating mental health conditions



McGill University





As psychedelics gain traction as potential treatments for mental health disorders, an international study led by researchers at McGill University, Imperial College London, and the University of Exeter stands to improve the rigour and reliability of clinical research.

Up to now, psychedelic clinical trials have had what has been widely acknowledged as a critical flaw: the failure to properly account for how a person’s mindset and surroundings influence the effects of psychedelics such as MDMA and psilocybin. This gap has led to inconsistent study results, making regulatory approval more difficult.

To address this, the researchers conducted a Delphi consensus study, bringing together 89 experts from 17 countries for a multi-round debate. The result is the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, published in Nature Medicine, a 30-item checklist, representing the first global agreement on which psychosocial factors have the greatest impact on a psychedelic experience.

“For decades, we’ve known that psychedelics don’t work in isolation. The person’s mindset, the therapy room, even the music playing all influence outcomes,” said co-lead author Chloé Pronovost-Morgan, a researcher at McGill University and Imperial College London. “Two trials using the same psychedelic drug, at the same dose, can produce completely different results depending on the environment.”

This approach challenges the way psychoactive drugs are typically studied, where scientists try to control or eliminate outside variables to isolate a drug’s effects. These guidelines recognize that context is crucial and should be studied directly.

Why guidelines matter

By offering a standard framework for evaluating and reporting these variables, the guidelines aim to make trial outcomes more consistent and comparable across studies.

Leor Roseman from the University of Exeter is co-senior author and said: “Having clear guidelines for contextual considerations is essential to understand the effects of psychedelics and how they work differently from other psychiatric medications. Our guidelines will also help in replicating results and understanding the true therapeutic potential of psychedelics.”

The lack of standards has had consequences beyond the research lab, Pronovost-Morgan explained. The U.S. Food and Drug Administration recently rejected MDMA-assisted therapy for post-traumatic stress disorder, citing inconsistent reporting across trials as a key reason for the decision.

“There is immense public interest in psychedelic therapies, particularly for individuals suffering from debilitating mental health conditions like PTSD, depression and anxiety, which have not responded to existing treatments,” said co-senior author Kyle Greenway, Assistant Professor in McGill’s Division of Social and Transcultural Psychiatry and a researcher at the Lady Davis Institute for Medical Research.

“Our guidelines offer a new gold standard for psychedelic research, helping bring these treatments to those who need them most.”

The research team is organizing a three-day workshop in October, funded by McGill’s Healthy Brains, Healthy Lives initiative, where leading experts in psychedelics and neuroscience will discuss how the guidelines can be integrated into research and clinical practice.

About the study

The Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) Guidelines: An international Delphi consensus study” by Chloé Pronovost-Morgan, Kyle Greenway and Leor Roseman was published in Nature Medicine.

This research was supported by the Imperial College London Societal Engagement Seed Fund.

Psilocybin enters gastroenterology: First-ever psychedelic study targets treatment-resistant IBS



Massachusetts researcher explores how childhood trauma becomes "somatically encoded" in gut disorders




Genomic Press

Erin Mauney, MD, Tufts University, USA. 

image: 

Erin Mauney, MD, Tufts University, USA.

view more 

Credit: Erin Mauney





BOSTON, Massachusetts, USA, 3 June 2025 – In a comprehensive Genomic Press Interview published today, Dr. Erin E. Mauney reveals how her pioneering research brings psychedelic medicine into gastroenterology for the first time, potentially transforming treatment for millions suffering from intractable irritable bowel syndrome (IBS).

The assistant professor of pediatrics at Tufts University, who maintains a research appointment at Massachusetts General Hospital, leads the first clinical trial examining psilocybin's effects on treatment-resistant IBS. Her work addresses a critical gap in medicine: the substantial population of IBS patients who find no relief through conventional therapies.

Breaking New Ground in Gut-Brain Medicine

Dr. Mauney's research explores how psilocybin modulates interoception – the way people perceive their body and gastrointestinal symptoms. The study protocol involves two doses of psilocybin with integrated therapy sessions before and after dosing, combined with neuroimaging via fMRI to track brain changes.

"I became very interested in the applicability of this emerging field of psychedelic-assisted medicine to patients who seem to be at war with their bodies," Dr. Mauney explains in the interview. Her approach recognizes that many patients with severe, unexplained somatic symptoms have experienced significant trauma, particularly in early life.

The research emerges from Dr. Mauney's observation that medicine, especially gastroenterology and obesity medicine, often fails to meaningfully understand and address the cumulative effects of toxic stress over the lifespan. This insight led her to investigate how early-life trauma becomes "somatically encoded" and how psychedelic therapy might create pathways for emotional release and functional improvement.

From Personal Curiosity to Professional Innovation

Dr. Mauney's journey into psychedelic research began during the pandemic when she read Michael Pollan's "How to Change Your Mind" while deciding to specialize in pediatric gastroenterology. Her background combines bacteriology research, including work on immune tolerance-inducing bacteria, with clinical expertise in integrative gastroenterology.

A setback that proved fortuitous occurred when Dr. Mauney wasn't accepted to her top fellowship choice at Boston Children's Hospital. Instead, she matched at Massachusetts General Hospital, where she gained access to mentors including Dr. Franklin King at the Center for the Neuroscience of Psychedelics and Dr. Brad Kuo at the Center for Neurointestinal Health – connections that would prove instrumental in launching her psychedelic research program.

Addressing the Mind-Body Divide

The study's significance extends beyond IBS treatment. Dr. Mauney hopes her work will help heal what she describes as "the schism between mind and body that so many physicians practice within." This artificial separation has long hindered effective treatment for functional gastrointestinal disorders, where psychological and physical symptoms intertwine.

Her research methodology combines quantitative measures – including patient-reported abdominal pain scores – with qualitative patient reflections and neuroimaging data. This multi-faceted approach aims to capture both the subjective experience of healing and objective biological changes. Could this integrated methodology become a model for studying other functional disorders where conventional treatments fall short?

Implications for Pediatric Medicine

While Dr. Mauney's current research focuses on adults, her pediatric background deeply informs her perspective. She notes that witnessing inequality and injustice daily in pediatrics, particularly regarding childhood obesity, motivates her broader vision for medicine. Her interest in pediatric obesity prevention requires what she calls "a full-scale realignment of our society's priorities," including food subsidies, urban design, educational approaches, and technology's impact on childhood.

This systemic thinking raises important questions: How might early intervention with trauma-informed approaches prevent the development of chronic functional disorders? What role could psychedelic therapy eventually play in addressing treatment-resistant conditions across the lifespan?

Personal Philosophy Shapes Scientific Approach

The interview reveals how Dr. Mauney's personal values influence her research approach. She emphasizes cultivating "honest, genuine relationships with each person you work with" and creating environments where people can bring their whole selves to work. Her motto, "We are what we repeatedly do," reflects her commitment to meticulous, persistent research that prioritizes patient wellbeing.

When asked about her greatest passion, Dr. Mauney responds: "Restoring humanity to the practice of medicine." This philosophy permeates her research design, which treats patients as whole persons rather than collections of symptoms. Her approach suggests a paradigm shift in how we conceptualize and treat functional disorders – moving from symptom suppression to addressing root causes, including psychological trauma.

Looking Forward: Scalable Solutions

Dr. Mauney's research aims not just to prove efficacy but to develop scalable therapeutic options. She envisions optimizing psychedelic therapy protocols to make them accessible in clinical settings, potentially offering hope to the millions of IBS patients worldwide who have exhausted conventional treatment options.

The timing of this research is particularly significant as psychedelic medicine gains mainstream acceptance. With multiple psychedelic compounds in late-stage clinical trials for various conditions, Dr. Mauney's work positions gastroenterology at the forefront of this therapeutic revolution. What other specialty areas might benefit from similar innovative approaches to treatment-resistant conditions?

Dr. Erin E. Mauney's Genomic Press interview is part of a larger series called Innovators & Ideas that highlights the people behind today's most influential scientific breakthroughs. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that delve into the scientist's impact on the field, while also touching on broader human themes. More information on the research leaders and rising stars featured in our Innovators & Ideas – Genomic Press Interview series can be found in our publications website: https://genomicpress.kglmeridian.com/.

The Genomic Press Interview in Psychedelics titled "Erin Mauney: Psychedelics as modulators of the gut-brain interaction," is freely available via Open Access on 3 June 2025 in Psychedelics at the following hyperlink: https://doi.org/10.61373/pp025k.0020.

About Psychedelics: Psychedelics: The Journal of Psychedelic and Psychoactive Drug Research (ISSN: 2997-2671, online and 2997-268X, print) is a peer reviewed medical research journal published by Genomic Press, New York. Psychedelics is dedicated to advancing knowledge across the full spectrum of consciousness altering substances, from classical psychedelics to stimulants, cannabinoids, entactogens, dissociatives, plant derived compounds, and novel compounds including drug discovery approaches. Our multidisciplinary approach encompasses molecular mechanisms, therapeutic applications, neuroscientific discoveries, and sociocultural analyses. We welcome diverse methodologies and perspectives from fundamental pharmacology and clinical studies to psychological investigations and societal-historical contexts that enhance our understanding of how these substances interact with human biology, psychology, and society. Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/ Our full website is at: https://genomicpress.kglmeridian.com/


Erin Mauney: Psychedelics as modulators of the gut-brain interactions

Credit

Erin Mauney

 

Researchers uncover genetic keys to the increasing threat of H9N2 avian influenza




Chinese Academy of Sciences Headquarters
Phylogeny of HA genes and the infectivity 

image: 

Phylogeny of HA genes and the infectivity in organotypic-differentiated primary normal human bronchial epithelial (NHBE) cells, and horizontal transmission between ferrets of H9N2 AIVs

view more 

Credit: BI Yuhai





A new study published in Nature Microbiology has uncovered significant genetic and antigenic diversity among H9N2 avian influenza viruses (AIVs) circulating in poultry across China, highlighting the growing public health risk posed by H9N2 AIVs.

Although H9N2—first identified in China in 1994—has been targeted by ongoing vaccination strategies, it has remained the dominant subtype in poultry. Its persistence, along with increasing reports of human infections in recent years, has become a growing public health concern.

Previously, the molecular basis for the virus' cross-species transmission and zoonotic potential remained largely unclear. Now, however, a collaborative team led by Prof. BI Yuhai and Prof. George F. Gao (GAO Fu) from the Institute of Microbiology of the Chinese Academy of Sciences, together with Prof. SHI Weifeng of Ruijin Hospital at the Shanghai Jiao Tong University School of Medicine, has conducted a comprehensive investigation into the virus' genetic evolution, antigenic variability, and adaptive mutations. Their findings offer crucial insights concerning the virus' molecular mechanism for mammalian adaptation and evasion of human MxA gene-mediated innate immune responses.

Since 2014, Prof. BI Yuhai has organized teams from the Center for Influenza Research and Early-warning (CASCIRE) to conduct continuous surveillance and early warning of AIVs in China and study cross-species transmission mechanisms of AIVs. Surveillance in live poultry markets from 2019 to 2023 revealed that the A/chicken/Beijing/1/94 (BJ94) lineage of H9N2 AIVs has consistently dominated in poultry.

To better understand its evolutionary trajectory, the team developed a novel clade classification system for BJ94 viruses based on genetic distances and phylogenetic relationships. They also launched an online classification platform to enable global researchers to track and study H9 AIV evolution.

Using this framework, they identified ten hemagglutinin (HA) sub-subclades currently co-circulating among poultry, each exhibiting distinct antigenic variations. These differences may explain why the existing vaccines have been unable to curb the epidemic of H9N2 AIVs.

Additionally, the researchers found a rising prevalence of key mutations associated with increased infectivity and pathogenicity in mammals. Between 2021 and 2023, 99.46% of H9N2 isolates carried the HA-L226 mutation linked to human receptor binding; 96.17% contained the NP-N52 mutation associated with resistance to the human MxA antiviral protein; and 32.61% had the PB2-V627 mutation known to enhance polymerase activity in human cells.

Experiments demonstrated that strains harboring these mutations preferentially bound to human-type receptors, replicated efficiently in human cells, and were capable of direct contact and aerosol transmission in guinea pigs and ferrets—key indicators of zoonotic potential.

These results highlight the heightened zoonotic risks of H9N2 AIVs. This study underscores the urgent need for enhanced surveillance, updated vaccine strategies, and a deeper understanding of avian influenza virus evolution to mitigate the growing threat of H9N2 to public health.

This work was supported by the National Key R&D Program of China and the National Natural Science Foundation of China for Distinguished Young Scholar.

African swine fever not recently imported to Europe, has been around for years




Oxford University Press USA
Pigs GBE 

image: 

Photo of pigs in the high containment facility at The Pirbright Institute, Pirbright, Surrey, UK.

view more 

Credit: Lauren Cresser, The Pirbright Institute/Genome Biology and Evolution




A new study in Genome Biology and Evolution, published by Oxford University Press, finds that the African Swine Fever virus, currently circulating in Europe, is not the result of a recent introduction. Instead, the virus has been present in the region since 2007. Its current dramatic spread appears to be driven largely by people within Europe traveling longer distances.

African Swine Fever virus is a highly virulent DNA virus that causes a severe hemorrhagic disease of the same name affecting both domestic pigs and wild boars. The disease is characterized by high mortality rates, leading to significant economic losses in the pork industry. According to estimates from the Food and Agriculture Organization, the virus has led to approximately $2.1 billion in direct economic losses over the past 17 years. Additionally, the outbreak has destroyed many small and medium-sized farms, contributing to structural transformations in agricultural markets, notably in China. Currently, there is no vaccine against the virus available widely.

Initially limited to the sub-Saharan African region, the virus (specifically genotype II) spread globally and is now a major concern in Africa, Europe, Asia, the Pacific and, more recently, the Caribbean. In 2024, the World Organization for Animal Health reported African Swine Fever virus outbreaks in seven European countries, with over one million pigs lost since 2022.

The researchers here analyzed ten samples from domestic pigs and wild boar, collected between July 26, 2016, and August 23, 2019, as part of the State Food and Veterinary Service of the Republic of Lithuania surveillance activities in Lithuania. From these samples, they generated complete genome sequences of African Swine Fever Virus. Researchers used these new sequences to expand the existing dataset of African Swine Fever Virus genomes genotype II and study of the spread of the virus across the European continent.

The analysis shows the African Swine Fever Virus genotype II now circulating in Europe shares a single common ancestor with those circulating in Africa, with no evidence of recent viral exchanges between the two continents. Sequences from Europe are closely related to each other and some countries, particularly Poland, Lithuania, Ukraine, and Germany, appear to have played important roles in the regional spread of the virus across the continent.

“African swine fever virus continues to threaten domestic pig and wild boar populations in Europe," said the paper’s lead author, Christopher Netherton. “Each viral genome we sequence helps to deepen our understanding of the virus’s circulation dynamics.”

The paper, “Exploiting viral DNA genomes to explore the dispersal history of African swine fever genotype II lineages in Europe,” is available (at midnight on June 3rd) at https://academic.oup.com/gbe/article-lookup/doi/10.1093/gbe/evaf102.

Direct correspondence to: 
Christopher L. Netherton
The Pirbright Institute
Ash Road
Pirbright, Woking. UNITED KINGDOM
christopher.netherton@pirbright.ac.uk

To request a copy of the study, please contact:
Daniel Luzer 
daniel.luzer@oup.com

Cracking nanomedicine’s hidden safety challenge


By Dr. Tim Sandle
DIGITAL JOURNAL
June 2, 2025


Washington has expanded its efforts in recent years to curb exports of state-of-the-art chips to China, concerned that these can be used to advance Beijing's military systems and otherwise undermine American dominance in A
I
- Copyright AFP ANTHONY WALLACE

Nanomedicines, especially those based on nanoparticles, have the promise to revolutionise healthcare in terms of both diagnostics and therapeutics. These particles, often containing metals like iron or gold, can serve as contrast agents in medical imaging, act as nutritional supplements, and even function as carriers for drug delivery.

Due to their unique properties plus careful engineering, nanomedicines can reach and accumulate in places within the body that conventional medicines cannot, making them promising for cancer detection and treatment. However, the same characteristics that make nanomedicines valuable also present challenges in ensuring their safety and quality.

Researchers have recently developed a breakthrough method to separately quantify ions, nanoparticles, and aggregates of the same metal in nanomedicines—an issue current global regulations overlook. Published in the journal Talanta, this tool sets a new standard for nanomedicine regulation.

The researchers combined two existing tools (AF4 + ICP-MS) in a novel way to pinpoint exactly what’s inside nanomedicines—making this a must-cover for anyone reporting on health, science, or tech safety.

Why it matters:⚠️ Current safety guidelines treat all forms of a metal as equal—missing toxicity risks.
💊 Ensures safer cancer drugs and contrast agents.
🌿 Can also be applied to food, cosmetics, and environmental testing.

With this study, the researchers combined two existing technologies—asymmetric flow field-flow fractionation (AF4) and inductively coupled plasma mass spectrometry (ICP-MS). They used the AF4 method in a novel way, taking advantage of its initial ‘focus step.’ During this step, particles are held inside the AF4 channel by two opposing flows.

Using a special permeable membrane, cross-flows filter out the tiniest dissolved particles (ions), enabling quantification based on the differences in ICP-MS signals between samples with and without ion removal−namely, with and without the focus step. Once the ions are separated, the system then uses AF4’s standard separation process to sort the retained nanoparticles by size. Finally, the ICP-MS device attached to the output can determine the approximate number of nanoparticles of each size.

This combination enabled the team to distinguish between free metal ions, small hydroxide colloids, and nanoparticles of various sizes, all containing the same metal element.

The scientists tested their approach on Resovist, a nanomedicine used as a contrast agent in liver magnetic resonance imaging scans. The analysis revealed that only 0.022% of the iron in Resovist was present in ionic form. At approximately 6.3 micrograms per milliliter, this negligible amount falls well below levels of concern.

Additionally, the team confirmed that the active nanoparticles were smaller than 30 nanometers in diameter, with some aggregates around 50 nanometers. Importantly, no large aggregates were detected, which could reduce the effectiveness of the contrast agent. These results confirm both the safety and stability of Resovist® as a nanomedicine.

The proposed technique is particularly relevant for emerging cancer treatments that use gold nanoparticles as drug delivery systems or metallic particles for photothermal therapy.

These advanced treatments rely on the ‘enhanced permeability and retention (EPR) effect,’ by which nanoparticles leak from blood vessels around tumours and accumulate in cancerous tissue.

Additionally, this novel analytical approach extends beyond pharmaceuticals. It can also assess the safety of metal nanoparticles in food additives, cosmetics, and environmental samples—helping to ensure public health across multiple sectors. The researchers showcased its versatility by successfully analyzing both negatively charged ions (silicon) and positively charged ions (iron), indicating its potential for a wide range of nanomaterials.

Overall, by offering a more comprehensive assessment of the composition, quality, and stability of nanoparticles, this research paves the way for safer and more effective nanomedicines and nanoparticle-based technologies.

The research is titled “Evaluation of elemental impurities and particle size distribution in nanomedicine using asymmetric flow field-flow fractionation hyphenated to inductively coupled plasma mass spectrometry.”